Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic PD-L1 Positive (CPS≥1) Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Next Previous
Trial Profile

Phase 2 Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic PD-L1 Positive (CPS≥1) Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Sargramostim (Primary) ; UV 1 (Primary)
  • Indications Carcinoma; Head and neck cancer; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FOCUS

Most Recent Events

  • 25 Oct 2024 According to an Ultimovacs AS media release, company announced that the results from Phase II FOCUS trial have been published online on the preprint platform medRxiv.
  • 21 Aug 2024 According to an Ultimovacs AS media release, the key findings and analyses from the FOCUS trial will be submitted for publication in a peer-reviewed medical journal.
  • 05 Aug 2024 Primary endpoint has not been met. (Progression free survival rate [ Time Frame: 6 months after first administration of study medication ]), according to an Ultimovacs AS media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top